TSX: HSM     OTC: HSDT

Call us: +1 877-564-0008

newsBanner

HELIUS MEDICAL TECHNOLOGIES GRANTS STOCK OPTIONS

(Newtown PA) – August 17, 2015 – Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( “Helius” or “the Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 50,000 shares of the Company, to an employee of Helius.

All options are subject to any earlier termination in accordance with their terms. The options are exercisable at a price of CAD $0.98, with one-third of such options vesting on the date of grant, another one-third vesting on the 1st anniversary of the date of grant and  the final one-third vesting on the 2nd anniversary of the date of grant.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to develop, license and acquire unique and non-invasive technologies that amplify the brain’s ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

# # #

Contact:

Corporate Contact:
Phil Deschamps

614-596-2597

pdeschamps@heliusmedical.com

Investor Relations:

778-588-7144

info@heliusmedical.com

Media Contact:

Becky Kern

914-772-2310

media@heliusmedical.com